Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam PK in Hepatic Impairment
NCT06390410Phase 1Completed
- Sponsor
- Cassava Sciences
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simufilam in Alzheimer's disease (AD) (3 arms), sponsored by Cassava Sciences. Primary endpoints: Area Under the Curve at 5 Days, Maximum Plasma Concentration at 5 Days and 3 more. Started Jun 2024; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06390410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390410.